Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
Launched by UNIVERSITY OF CONNECTICUT · Jan 18, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of daily consumption of milk polar lipids (MPLs) on heart and metabolic health in adults with high cholesterol and abdominal obesity. Researchers want to find out if these milk components can help improve risk factors related to heart disease and other metabolic conditions. The trial is currently recruiting participants aged 18 to 70 who have elevated LDL cholesterol levels (often referred to as "bad" cholesterol) and specific waist measurements, indicating abdominal obesity.
To join the study, participants must meet certain criteria, such as having high LDL cholesterol and a waist size that exceeds 88 cm for women or 102 cm for men. However, individuals with certain health issues, like diabetes, heart disease, or those taking specific medications for cholesterol or inflammation, are not eligible. If you choose to participate, you will help researchers understand more about the potential benefits of milk polar lipids, and you may receive valuable insights about your own health during the process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • LDL-C ≥ 130 mg/dL
- • Waist circumference ≥ 88 cm for women, ≥ 102 cm for men
- • Aged 18 to 70 years
- Exclusion Criteria:
- • Renal disease
- • Liver disease
- • Diabetes
- • Heart disease
- • Stroke
- • Cancer
- • Eating disorders
- • Thyroid disease
- • Gut-associated pathologies
- • Autoimmune diseases
- • Chronic inflammatory diseases
- • Scleroderma
- • Gallbladder disease
- • Blood clotting disorders
- • Intravenous drug use
- • Fasting plasma/serum triglycerides \>500 mg/dL
- • Fasting plasma/serum glucose \>126 mg/d
- • Weight changes \>10% over last 4 weeks
- • Oral antibiotics use up to 1 month prior to and during study
- • Allergy or intolerance to milk products
- • Taking lipid-lowering medications (e.g., statins, fibrates)
- • Taking anti-inflammatory medications (e.g., corticosteroids)
- • Taking medications which primarily affect blood clotting (e.g., warfarin).
About University Of Connecticut
The University of Connecticut (UConn) is a leading academic institution committed to advancing health and science through innovative research and education. As a clinical trial sponsor, UConn leverages its extensive resources, including renowned faculty and state-of-the-art facilities, to conduct rigorous studies that contribute to medical knowledge and improve patient care. The university fosters a collaborative environment, engaging multidisciplinary teams to explore novel therapies and interventions across various health-related fields. UConn's dedication to ethical practices and compliance ensures the integrity and reliability of its clinical research, ultimately aiming to enhance health outcomes and address critical challenges in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Storrs, Connecticut, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials